Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 21;9(2):144.
doi: 10.3390/jof9020144.

Systemic Antifungal Therapy for Invasive Pulmonary Infections

Ronen Ben-Ami  1
Affiliations
Review

Systemic Antifungal Therapy for Invasive Pulmonary Infections

Ronen Ben-Ami. J Fungi (Basel). .

Abstract

Antifungal therapy for pulmonary fungal diseases is in a state of flux. Amphotericin B, the time-honored standard of care for many years, has been replaced by agents demonstrating superior efficacy and safety, including extended-spectrum triazoles and liposomal amphotericin B. Voriconazole, which became the treatment of choice for most pulmonary mold diseases, has been compared with posaconazole and itraconazole, both of which have shown clinical efficacy similar to that of voriconazole, with fewer adverse events. With the worldwide expansion of azole-resistant Aspergillus fumigatus and infections with intrinsically resistant non-Aspergillus molds, the need for newer antifungals with novel mechanisms of action becomes ever more pressing.

Keywords: antifungal drug; antifungal resistance; invasive aspergillosis; mucormycosis.

PubMed Disclaimer

Conflict of interest statement

Dr. Ben-Ami has served on advisory boards for Pfizer and Merck and received compensation from Teva and Gilead for lectures.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bongomin F., Gago S., Oladele R.O., Denning D.W. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J. Fungi. 2017;3:57. doi: 10.3390/jof3040057. - DOI - PMC - PubMed
    1. Webb B.J., Ferraro J.P., Rea S., Kaufusi S., Goodman B.E., Spalding J. Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network. Open Forum Infect. Dis. 2018;5:ofy187. doi: 10.1093/ofid/ofy187. - DOI - PMC - PubMed
    1. Nnadi N.E., Carter D.A. Climate change and the emergence of fungal pathogens. PLoS Pathog. 2021;17:e1009503. doi: 10.1371/journal.ppat.1009503. - DOI - PMC - PubMed
    1. Ashraf N., Kubat R.C., Poplin V., Adenis A.A., Denning D.W., Wright L., McCotter O., Schwartz I.S., Jackson B.R., Chiller T., et al. Re-drawing the Maps for Endemic Mycoses. Mycopathologia. 2020;185:843–865. doi: 10.1007/s11046-020-00431-2. - DOI - PMC - PubMed
    1. Nett J.E., Andes D.R. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. Infect. Dis. Clin. N. Am. 2016;30:51–83. doi: 10.1016/j.idc.2015.10.012. - DOI - PubMed

LinkOut - more resources